ConductScience.org, home

Trial · NCT01272037

Results by group286

Each measurement the trial posted, group by group, in the words and numbers it posted.

OutcomeGroupCategoryValueSpreadUnits
Invasive Disease-Free Survival (IDFS)Chemo and Endocrine TherapyPremenopausal93.9percentage of participants
Invasive Disease-Free Survival (IDFS)Endocrine Therapy AlonePremenopausal89.0percentage of participants
Invasive Disease-Free Survival (IDFS)Chemo and Endocrine TherapyPostmenopausal91.3percentage of participants
Invasive Disease-Free Survival (IDFS)Endocrine Therapy AlonePostmenopausal91.9percentage of participants
Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study DrugsChemo and Endocrine TherapyAbdominal infection1Participants
Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study DrugsEndocrine Therapy AloneAbdominal infection0Participants
Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study DrugsChemo and Endocrine TherapyAbdominal pain7Participants
Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study DrugsEndocrine Therapy AloneAbdominal pain0Participants
Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study DrugsChemo and Endocrine TherapyAcute kidney injury1Participants
Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study DrugsEndocrine Therapy AloneAcute kidney injury0Participants
Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study DrugsChemo and Endocrine TherapyAlanine aminotransferase increased4Participants
Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study DrugsEndocrine Therapy AloneAlanine aminotransferase increased2Participants
Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study DrugsChemo and Endocrine TherapyAlkaline phosphatase increased1Participants
Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study DrugsEndocrine Therapy AloneAlkaline phosphatase increased0Participants
Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study DrugsChemo and Endocrine TherapyAllergic reaction6Participants
Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study DrugsEndocrine Therapy AloneAllergic reaction1Participants
Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study DrugsChemo and Endocrine TherapyAnemia20Participants
Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study DrugsEndocrine Therapy AloneAnemia0Participants
Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study DrugsChemo and Endocrine TherapyAnorexia2Participants
Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study DrugsEndocrine Therapy AloneAnorexia0Participants

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01272037/results